TY - JOUR
T1 - Soluble ST2 - Analytical considerations
AU - Mueller, Thomas
AU - Jaffe, Allan S.
N1 - Funding Information:
Publication of this supplement was supported by funding from Critical Diagnostics, San Diego, CA.
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/4/2
Y1 - 2015/4/2
N2 - Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a "decoy" receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts.
AB - Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a "decoy" receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts.
UR - http://www.scopus.com/inward/record.url?scp=84924977569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924977569&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2015.01.035
DO - 10.1016/j.amjcard.2015.01.035
M3 - Review article
C2 - 25697919
AN - SCOPUS:84924977569
SN - 0002-9149
VL - 115
SP - 8B-21B
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 7
ER -